Table 1.
Baseline patient characteristics and study follow-up
| TE (n=148) | PTE (n=129) | VC ± combined phaco (n=104) | p-value | |
|---|---|---|---|---|
| Gender | 0.4184 | |||
| Male, n (%) | 72 (48.6) | 71 (55.0) | 46 (44.2) | |
| Female, n (%) | 76 (51.4) | 58 (45.0) | 58 (55.8) | |
| Age | 0.4927 | |||
| Mean (SD) | 63.5 (11.1) | 68.34 (11.4) | 67.9 (8.8) | |
| Range | 39–81 | 59–80 | 52–82 | |
| Glaucoma type | 0.1350 | |||
| POAG, n (%) | 126 (85.1) | 105 (81.4) | 88 (84.6) | |
| PACG, n (%) | 13 (14.9) | 24 (18.6) | 16 (15.4) | |
| Ocular characteristics | 0.3137 | |||
| Left eye, n (%) | 77 (52.0) | 72 (55.8) | 52 (50.0) | |
| Right eye, n (%) | 71 (48.0) | 57 (44.2) | 52 (50.0) | |
| Presenting IOP | 0.0980 | |||
| mmHg (SD) | 26.4 (9.5) | 25.2 (7.1) | 23.8 (6.8) | |
| Range | 10–66 | 12–55 | 11–48 | |
| Preoperative IOP | 0.0199 | |||
| mmHg (SD) | 23.2 (7.1) | 23.4 (8.3) | 20.2 (4.2) | |
| Range | 8–42 | 10–47 | 12–35 | |
| Preoperative IOP-lowering medications | 0.04486 | |||
| Number of medications, n (SD) | 2.7 (0.9) | 2.5 (0.9) | 2.3 (0.9) | |
| Preoperative BCVA | 0.0009 | |||
| Median LogMAR (IQR) | 0.18 (0.02–0.22) | 0.2 (0.18–0.32) | 0.3 (0.18–0.5) | |
| Preoperative HVF 24-2 | 0.0176 | |||
| MD (SD) | −12.96 (6.72) | −13.90 (7.49) | −12.77 (8.44) | |
| Total follow-up (months) | ||||
| Mean (SD) | 22.1 (11.3) | 23.2 (11.5) | 26.5 (13.3) | |
| Range | 12–60 | 12–48 | 12–60 |
Abbreviations: TE, trabeculectomy; PTE, phacotrabeculectomy; VC, viscocanalostomy; phaco, phacoemulsification/intraocular lens; POAG, primary open-angle glaucoma; PACG, primary angle closure glaucoma; IOP, intraocular pressure; BCVA, best-corrected visual acuity; IQR, interquartile range; HVF, Humphrey visual field; MD, mean deviation.